

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE
 in its capacity as elected Office

Date of mailing (day/month/year) 27 March 2001 (27.03.01)	
International application No. PCT/GB00/02738	Applicant's or agent's file reference GWS/21495
International filing date (day/month/year) 17 July 2000 (17.07.00)	Priority date (day/month/year) 16 July 1999 (16.07.99)
Applicant CODD, Anthony, Arthur	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
 24 January 2001 (24.01.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Juan Cruz Telephone No.: (41-22) 338.83.38
--	--

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

<p>To:</p> <p>SCHLICH, George, William MATHYS & SQUIRE 100 Gray's Inn Road LONDON, Greater London WC1X 8AL GRANDE BRETAGNE</p>	<div style="border: 1px solid black; padding: 5px;"> RECEIVED MATHYS & SQUIRE 25 OCT 2001 REPLY DATE DIARY ENTERED </div>	<p style="font-size: 2em; text-align: center;">PCT</p> <p style="text-align: center;">NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT (PCT Rule 71.1)</p>
<p>Applicant's or agent's file reference GWS/21495</p>		<p>Date of mailing (day/month/year) 18.10.2001</p>
<p>International application No. PCT/GB00/02738</p>	<p>International filing date (day/month/year) 17/07/2000</p>	<p>Priority date (day/month/year) 16/07/1999</p>
<p>Applicant PUBLIC HEALTH LABORATORY SERVICE BOARD et al.</p>		

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

<p>Name and mailing address of the IPEA/</p> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"> <p>European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465</p> </div>	<p>Authorized officer</p> <p>Hingel, W</p> <p>Tel. +49 89 2399-8717</p>
--	---



PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference GWS/21495	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/GB00/02738	International filing date (<i>day/month/year</i>) 17/07/2000	Priority date (<i>day/month/year</i>) 16/07/1999
International Patent Classification (IPC) or national classification and IPC C12N5/00		
Applicant PUBLIC HEALTH LABORATORY SERVICE BOARD et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 6 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 5 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 24/01/2001	Date of completion of this report 18.10.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Roscoe, R Telephone No. +49 89 2399 2554 

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB00/02738

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-26 as originally filed

Claims, No.:

1-34 as received on 30/07/2001 with letter of 27/07/2001

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/02738

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	10-12, 14, 15, 17-26, 33, 34
	No:	Claims	1-9, 13, 16, 27-32
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-34
Industrial applicability (IA)	Yes:	Claims	1-34
	No:	Claims	

2. Citations and explanations
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

V. Reasoned statement on Novelty, Inventive Step and Industrial Applicability

The documents mentioned in the present International Preliminary Examination Report are numbered as in the search report, i.e. D1 corresponds to the first document of the search report etc.

Novelty (Art.33(2) PCT)

D1 discloses preparation of lenticules by suspension of bacteria in Codd's medium and subsequent drying. Since Codd is one of the present inventors it is assumed that this is effectively a disclosure of the invention. However, the composition of Codd's medium is not disclosed in D1, neither is a reference to the medium as such provided. Hence, unless it later turns out that the composition of the medium had previously been made available to the skilled person, D1 is not an enabling disclosure which can be considered to anticipate the present invention.

D2 discloses a vaginal lactobacillus medicament. The preservation matrix is described on p.6-7. The solution in which the bacteria is suspended comprises carbohydrate incl. lactose / maltose / sucrose (all non-reducing disaccharides). Further, have binding agent such as gum or carboxymethyl cellulose (can be considered as bulking agent or as structural agent), antioxidant, polyol, and a proteinaceous material such as albumin (can be considered as bulking agent or as structural agent). The components are suspended in water.

D3 discloses a preservation solution (not for subsequent drying) for biological materials in general, with emphasis on mammalian tissues. No mention of application to microorganisms, but may nevertheless be suitable therefor. The solution comprises 2 neutral solutes: (i) neutral solute of no net charge, M.W. > 335 (thus too large to penetrate cell membrane but able to raise osmolarity of solution) - e.g. sucrose / lactose, and (ii) neutral solute M.W. < 200 (can be actively taken up by cells in response to osmotic insult) having both hydrophilic and hydrophobic moieties (e.g. glucose). No buffer is involved although it is noted that the term buffer is in itself relatively problematic since many compounds can have a minor buffering effect under certain conditions. Not cited against novelty.

D4 discloses a preservation solution comprising (i) buffer (col.8) and (ii) cryoprotectant(s) / dry protectants (col.9). Trehalose is often mentioned and has both cryoprotectant and dry protectant properties and is thus considered as the preferred component in D4. Looking at the buffers in D4, there are 6 specific buffer options which are mentioned in col.8, including (2) LISP buffer which comprises glucose. The cryoprotectant can be trehalose / sucrose or HSA, or further compounds or combinations thereof. D4 explicitly mentions amongst others the combination trehalose and HSA. The combination of trehalose and HSA in LISP buffer appears to anticipate claim 1 (it does not matter that the glucose is in the LISP buffer - the buffer would still have a buffering effect without the glucose and it does not matter that claim 1 is separated into components (a) and (b) because all of the components are found together in the composition. The composition is for use in cryopreservation and subsequent drying of bacteria or viruses. Hence, the present method claims which explicitly do not involve cryopreservation i.e. claims 18-26 (and are not open-ended, thus allowing addition of a cryopreservation step as in claims 31-34) are not anticipated. D4 anticipates claims 1-9, 13, 16, 27-32.

D5 discloses a stabilizing solution for viral lyophilization. The solution comprises phosphate buffer (pH 7.3), lactose and HSA.

- **Inventive Step (Art.33(3) PCT)**

No overriding inventive concept is evident in the present application. A number of claims are not even novel (it is noted that the remaining claims are not linked by even a novel concept and are thus not unitary. Use of a particular disaccharide (non-inventive selection if even considered novel, not shown to be associated with surprising properties), addition of monosaccharides (e.g. glucose) disclosed in D3, structural additives (too vague to address), colouring agent (found in D1), particular processes of cooling or drying (various prior art documents), or counting of organisms (which could even be considered as intrinsic to the prior art) do not prima facie appear to establish inventive activity.

- **Industrial Applicability (Art.33(4) PCT)**

The present claims appear to have industrial applicability.

VIII. Certain observations

- Clarity (Art.6 PCT)

Claim 4 - applicant should specify by which method M.W. has been determined.

Claim 10 - structural additive - could be anything

Claim 18 - replacement of triple point of water with mere temperature indication seems insufficient since basis refers to both temperature and pressure in one breath (see p.13, l.21-). Although definition of pressure as not being "significantly below atmospheric" is not very clear due to term "significant", the addition of this terminology would avoid the more serious problem of introducing added matter by the omission of a feature.

Claim 27 - % by weight or volume

Claim 29 - definition by result to be achieved

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05941 A2

(51) International Patent Classification⁷: C12N 5/00

(21) International Application Number: PCT/GB00/02738

(22) International Filing Date: 17 July 2000 (17.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9916790.0 16 July 1999 (16.07.1999) GB

(71) Applicant (*for all designated States except US*): PUBLIC HEALTH LABORATORY SERVICE BOARD [GB/GB]; 61 Colindale Avenue, London NW9 5DF (GB).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): CODD, Anthony, Arthur [GB/GB]; Darras Hall, 213A Western Way, Ponteland, Northumberland NE20 9ND (GB).

(74) Agents: SCHLICH, George, William et al.; Mathys & Squire, 100 Gray's Inn Road, London WC1X 8AL (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STORAGE OF MICROORGANISMS, CELLS AND TISSUE

(57) Abstract: A composition for preserving viable microorganisms, cells or tissue comprises (a) a preservative combination of (i) a non-reducing disaccharide and (ii) a bulking agent; and (b) a buffer. Also described is a method of preserving viable microorganisms, cells or tissue, comprising combining viable microorganisms, cells or tissue with a preserving solution comprising a non-reducing disaccharide, drying the combination to form a dried preparation having a solids content of at least 80 % by weight, and counting the viable microorganisms, cells or tissue in the dried preparation, whereby the dried preparation can be combined with aqueous buffer to yield an aqueous preparation comprising a predetermined count of viable microorganisms, cells or tissue.



WO 01/05941 A2

- 1 -

STORAGE OF MICROORGANISMS, CELLS AND TISSUE

This invention relates to the storage of microorganisms, cells and tissue. The invention may be applied to the storage of a wide range of such biological materials but in particular has a special applicability to storing those biological materials that deteriorate at room temperature in aqueous solution. The invention in its most preferred aspect relates to the storage of microorganisms, cells and tissue in a viable state.

Many varieties of biological reagent are known to deteriorate rapidly when stored at room temperature, forcing the adoption of a range of methods for the storage and preservation of such reagents. Known methods include simple refrigeration, and freeze-drying and subsequent storage at ambient temperature. In some instances, no effective storage methods are available. Instead, an assessment is made of the deterioration of the sample between its preparation and analysis so that the original composition of the sample can be extrapolated.

A method of preserving microorganisms (including bacteria, yeast and fungi) is known that uses storage beads. A suspension of the microorganism is made in a cryopreservative and then mixed with storage beads. The cryopreservative is removed and the beads frozen and stored at a temperature of typically -70°C . To recover the microorganism, a bead is removed from frozen storage and placed in broth or rolled onto growth medium. This method has various drawbacks. Storage temperatures of 70°C require specialist refrigeration units. Freezing inevitably results in significant physical damage to the microorganism. Special cryopreservative is required, which can be expensive. Finally, the beads are typically of size 2-4mm diameter and are awkward to manipulate.

In some known instances it is required to obtain a viable count from a water sample that possibly contains bacteria. At present, this is routinely achieved

- 2 -

by transport of the test sample in solution from the place at which the test sample was obtained to the counting location. It is a known phenomenon that, during transport, the number of viable bacteria in the sample will decrease over time at a certain rate. To counter this, the bacterial count is taken at a very precise and predetermined time interval after the sample is taken. The count is then adjusted according to the calculated decrease in number since the sample was taken. Disadvantages inherent in this existing method include the danger of rupture of the vessel that contains the bacterial sample and the inconvenience of being forced to operate within a precise time scale intended to allow for the known rapid deterioration in viability of the bacterial sample over time.

EP-A-0229810 describes protection of proteins and like macromolecules using a solution of trehalose. However, the particular difficulties associated with storage of microorganisms is not addressed.

It is widely recognized that food safety is highly dependent on bacteriological methods that are capable of detecting small numbers of pathogenic bacteria in both raw and processed materials. Contamination below an infecting dose given favourable conditions for growth such that re-hydration of a dry product or exposure of a wet product to a high ambient temperature may soon become hazardous.

One of the problems of controlling the performance of routine microbiological tests on foods for the presence or absence of marker organisms is the provision of suitable standardized controls. Many laboratories rely on wet suspensions cryo-preserved on beads at -20°C for a number of weeks or broths refrigerated at 4°C and renewed weekly. The inocula are prepared by making a fixed dilution from the preserved suspensions but the actual counts obtained can vary widely depending on the density and viability of the organism. Freshly grown bacteria are usually less damaged than cells that have been resting for a while and will consequently have a higher

- 3 -

plating efficiency. However marker organism of interest to public health and the food industry are often in a non-replicating and damaged state. In addition they may have been subjected to thermal stress during the manufacturing process.

5

US-A-5733774 describes methods and compositions for producing stable bacterial formulations, and involves drying bacteria, combining them with a powder or granular non-aqueous carrier and packaging the bacteria in sealed packaging impermeable to gas and water vapour, the method also including removing substantially all oxygen from inside the package. The methods described, however, are impractical in that strenuous efforts must be taken to remove gas and water vapour and oxygen from the stored material. In addition, prolonged viability of stored bacteria has not been demonstrated.

10

15 WO-A-90/04329 describes storing mammalian cells in a process that includes lyophilizing mammalian cells and storage at about 4°C. The lyophilizing step introduces significant risk of loss of viability of the stored material.

20

WO-A-99/00485 discloses a composition for preserving microorganisms, using starch optionally mixed with albumin.

25

The present invention seeks to overcome or at least mitigate problems associated with the art and to provide improved storage of biological material such as microorganisms, cells and tissue.

30

It is therefore an object of the present invention to provide a method of storage of biological materials that does not require refrigeration below 0°C and does not require freezing of the stored material.

It is another object to provide a solid-state stored biological material that is stable to an acceptable degree and suitable for long-term storage at 4°C and

- 4 -

which can readily be re-constituted into a solution of biological material.

A further object is to provide a stored biological material which is suitable for transport, including via the postal system, without excessive risk of damage to the biological material during transport.

A more specific object of the invention is to provide a method of storing microorganisms, cells and tissue in a viable state for extended periods of time.

Accordingly, in a first aspect, the invention provides a method of preserving viable microorganisms, comprising drying an aqueous preparation of viable microorganisms, cells or tissue in the presence of non-reducing disaccharide to form a dried preparation, counting the viable microorganisms, cells or tissue in the dried preparation to obtain a counted dried preparation, and storing the counted dried preparation, wherein the counted dried preparation when reconstituted with water or aqueous medium forms an aqueous preparation containing a predetermined number of viable microorganisms, cells or tissue.

In a second aspect, the invention provides a composition for preserving viable microorganisms, cells or tissue, the composition comprising:

- (a) a preservative combination of (i) a non-reducing disaccharide and (ii) a bulking agent; and
- (b) a buffer.

In a third aspect, the invention provides a process for preserving viable microorganisms, cells or tissue, comprising the steps of:

- (a) combining the microorganisms, cells or tissue with the composition of the invention to form a preserving preparation;
- (b) drying the preserving preparation at above the triple point of water; and

- 5 -

(d) storing the dried preparation obtained.

It is an advantage of the invention that biological material such as microorganisms, cells or tissue can be stored for extended periods of time in a stable form and whilst retaining significant viability. Specific embodiments of the invention provide individual dried preparations of bacteria suitable for storage and which are readily reconstituted with water or other aqueous buffer to yield viable bacteria. Thus, a 25 μ l drop of bacterial suspension forms a lenticule with a dry weight of 8mg, containing from 10-10⁸ CFU's of single organisms or mixtures. It can be reconstituted for use in 10 minutes.

A further advantage of the invention over other methods of preserving viability in microorganisms is that samples of biological material can be prepared having a predetermined, known number of viable microorganisms, cells or tissue, due to the extended viability of stored material in compositions of the inventions. Samples can thus have a defined numbers of viable organisms per stored sample. Hence, they can be used for quantitative experiments, and in situations where presence or absence of very low-numbers of marker organisms is a stringent test of the processes being controlled.

Defined count preparations containing bacterial numbers ranging from 10 cfu to 10⁸ cfu have been prepared in accordance with the invention, stored and resuscitated with no significant loss of viability. The confidence limits of the cfu counts have been established by performing viable counts on multiple lenticules. The counts are usually within 95% confidence interval, even for the very low count preparations. The invention provides a versatile alternative to the maintenance of bacterial cultures either on slopes, wet suspensions at 4°C, cryo-preservation at low temperature, freeze-drying or spray-drying.

- 6 -

In use of the invention, a sample of biological material is combined with (a) a preservative combination of (i) a non-reducing disaccharide and (ii) a bulking agent; and (b) a buffer. The weight ratio of the non-reducing disaccharide:bulking agent is suitably 5:1 to 0.5:1, preferably about 3.5:1 to 1.5:1, and the solids content is generally at least 20% by weight.

The non-reducing disaccharide may be selected from the group consisting of trehalose, sucrose, maltose, lactose, cellobiose, isomers thereof and mixtures thereof. Preferably, trehalose or a combination of trehalose and other non-reducing disaccharide is used.

In compositions of the invention, the bulking agent typically is, or comprises, a high molecular weight protein. Preferably the bulking agent is a matrix protein which has a molecular weight which is less than 100kD and preferably is within the range 50-100kD. Most preferably the matrix protein is a relatively inert globular protein such as albumin. Gelatin, (which normally has a molecular weight in the range 170-200kD) is not suitable. Suitable albumins include ovalbumin, foetal calf albumin and lactalbumin. In an embodiment of the invention the matrix protein is serum albumin, or more specifically bovine serum albumin. The matrix protein is conveniently present in solution in an amount between 5 and 20g per 100ml, preferably 8-12g and more preferable around 10g per 100ml.

The buffer is selected so as to maintain the pH of the solution at a value at which the microorganisms, cells or tissues are stable and should contain components that do not selectably salt out as their concentration increases during the drying step. One suitable buffer is phosphate buffered saline (PBS) at a concentration between 0.1 and 1M, preferably 0.15-0.5M.

The above components act together to form a solution which when dried results in a solid, typically flexible, pellet containing the biological material that is being stored.

- 7 -

A particular embodiment of the invention comprises:

- (i) 5 to 30 wt% non-reducing disaccharide;
- (ii) 1 to 10 wt% bulking agent; and
- (iii) 60 to 94 wt% aqueous buffer.

5

The composition may further comprise a monosaccharide, for example a reducing sugar such as glucose. The monosaccharide can be present at 0.1 to 3 wt%.

10

It is further optional to include within the composition a structural additive, and this can be or comprise a water-soluble polymeric carbohydrate. In embodiments of the invention carboxymethylcellulose is used, though other additives are suitable, such as hydroxyalkylcellulose.

15

It is preferred that the structural additive be water soluble and that all other components be water soluble so that when a dried composition of the invention is reconstituted in water it dissolves substantially completely leaving a clear solution. Insoluble or partially soluble sugars and bulking are preferably avoided. Thus, starch which does not fully dissolve or dissolves leaving a cloudy preparation is preferably avoided.

20

A colouring agent is further optional.

25

The methods and compositions of the invention are particularly suited to storage of microorganisms, selected from the group consisting of bacteria, viruses, protozoa and fungi.

The solids content of compositions of the invention is initially generally in the range of from 10-50%.

30

Once biological material has been combined with the composition of the invention, it is preserved by drying at above the triple point of water, and

- 8 -

storing the dried preparation obtained. The drying step can readily be carried at atmospheric pressure, and good results have been so obtained in examples of the invention described in more detail below. Reduced pressure can also be used in drying the compositions.

5

Drying may also be carried out by passing a draught of air, inert gas or a mixture thereof over the preserving preparation in the presence of a drying agent. Silica gel can be used, as can other drying agents. It is also optional to use a substantially oxygen-free environment.

10

In a further embodiment of the invention, the process comprises:

- (i) partially drying the preserving preparation by passing a draught of air, inert gas or a mixture thereof over the preserving preparation in the presence of a drying agent; and
- 15 (ii) 15 subjecting the partially dried preserving preparation to further drying at reduced temperature.

20

In a particular embodiment of the invention, the process comprises depositing the preserving preparation onto a hydrophobic surface prior to drying. Preferably, a small volume of liquid is deposited and dried, forming a small solid composition, referred to as a pellet or lenticule. Once dried this pellet is highly convenient to handle. The volume of preserving preparation that constitutes a small volume can be in the range of from 5-100 μ l.

25

In a specific embodiment, the process of the invention as applied to bacteria is to heavily seed a supportive medium with a culture and incubate it optimally until early lag phase. On a standard 90mm plate the typical yield is 10^{11} colony forming units, CFU's. This growth is harvested into a small volume of low strength saline and mixed with 2.5ml of solution. 25 μ l spots
30 are dispensed onto a hydrophobic surface and dried above the triple point. The 100 or so resulting primary so-called lenticules each contain around 10^8 CFU's and are stored at about -20°C, above the eutectic, under desiccation.

- 9 -

Strains that have been preserved by the invention include *Staph. aureus*, *Staph. epidermidis*, *Bacillus cereus*, *Bacillus subtilis*, *Listeria monocytogenes*, *Str. faecalis*, *Str. pyrogenes*, *Str. agalactia*, *Str. pneumonia*, *Enterococcus faecium*, *Cl. perfringens*, *Sacchromyces*, *E coli* (including 0157), *Salmonella* sp, *Ps aeruginosa*, *Klebsiella* sp, *Proteus* sp, *Campylobacter* sp, *Helicobacter pylori*, *Vibrio parahaemolyticus*, *Acenitobacter* sp, *Serratia marcesans*, *Haemophilus influenzae*, *Bordetella pertussis*, *N. meningitidis*, *N. gonorrhea*, *Bacteroides* sp and *Salmonella gold coast*. Mycoplasma, viruses and fungi can also be preserved by the present invention.

Compositions of the invention may be supplied in a number of formats, e.g

- (1) on parafilm or similar hydrophobic surface;
- (2) loose; and
- (3) dried directly in microtiter strips, for all of these, storage at -20°C under desiccation assists a prolonged shelf life.

In a further aspect of the invention there is provided a dried composition according to the invention further comprising a viable microorganism and having a solids content of at least 80%. The viable microorganisms are preferably bacteria, or a mixture of bacteria of different strains, or a combination of bacteria and mammalian cells.

This aspect of the invention also provides a dried composition having a defined microorganism count wherein said microorganism count remains substantially stable in storage at ambient temperature. By defined count is meant that the content of the dried composition is known or predetermined, directly or indirectly, and that therefore once reconstituted with buffer an aqueous preparation is obtained having a defined count of viable microorganisms.

It is preferred that the composition is fully dispersible when reconstituted with water or aqueous buffer solution - ie that all components are water

- 10 -

soluble and readily dispersible.

A method of preserving viable microorganisms, cells or tissue of the invention comprises:-

5

(a) combining viable microorganisms, cells or tissue with a preserving solution comprising a non-reducing disaccharide;

10

(b) drying the combination of (a) to form a dried preparation having a solids content of at least 80% by weight; and

(c) counting the viable microorganisms, cells or tissue in the dried preparation;

15

whereby the dried preparation can be combined with aqueous buffer to yield an aqueous preparation comprising a predetermined count of viable microorganisms, cells or tissue.

20

To calculate the viable count it is preferred to form at least first and second dried preparations, counting the viable microorganisms, cells or tissue in the first dried preparation and thereby estimate the number of viable microorganisms, cells or tissue in the second dried preparation. Thus the count is made indirectly.

25

Where a large number of such dried preparations are made, the method can comprise counting a selected sample of those dried preparations so as to estimate the count of viable microorganisms, cells or tissue in the remaining dried preparations.

30

The drying step can be carried out in air or inert gas or mixtures thereof. In an embodiment, the drying step is carried out in an atmosphere of reduced oxygen concentration (compared to air), an advantage of this being that

- 11 -

oxidation of the biological material during the drying step is reduced. In another embodiment, the drying step is carried out in an atmosphere of reduced humidity. In a further embodiment, the pressure is reduced during drying.

5

The drying can conveniently be carried out at room temperature and can also be carried out at temperatures down to around 4°C. Higher drying temperatures could also be employed, though these would have to be weighed against the increased deterioration of the biological material caused by the increased temperature.

10

The drying step is intended to result in a solid composition containing the biological material and preferably having a water content in the region of less than 10 percent by weight. The water content is preferably in the range of 4-8 percent by weight and most preferably around 6 percent by weight (the term "around" allowing a tolerance of +/- 2%). As will be appreciated, the ideal water content of the solid stored composition will depend upon the nature of the material to be stored.

15

After the method has been used to produce a solid composition containing the biological material this then can be stored either at room temperature or, conveniently, at refrigeration temperature, typically around 4°C.

20

To re-constitute active biological material from the stored solid it is a fairly straight forward procedure to dissolve the stored solid in water or in buffer solution.

25

In embodiments of the invention the storage method is carried out under sterile conditions. Similarly, in embodiments of the invention the re-constitution of aqueous solution of biological material is carried out using sterile water or sterile buffer.

30

- 12 -

5 The invention is of application to biological material that cannot be stored indefinitely at room temperature in aqueous solution. A biological material may be regarded as having an unacceptable stability if it has a half life of less than 5 days, especially less than 2 days when stored at ambient temperature (20°C). Especially unstable biological material are ones having a half life of less than 24 hours. Examples of biological material that are suitable for storage according to the invention include microorganisms including bacteria and viruses, cells and samples of biological solutions such as serum samples.

10

In an embodiment of the invention, the storage method is used to store a bacterial sample. For storage of bacteria it is optional to include in the storage solution, prior to drying, a membrane stabilizing agent. Suitable membrane stabilizing agents include glycerol, egg yolk and mixtures thereof.

15

It is particularly advantageous to store microorganisms such as bacteria using the method of the invention as when the bacteria are in solid, stored form they are easy to handle and transport, including transport via the postal service. The bacterial in the stored form of the invention are relatively stable and this enables the viable count to be obtained over a more flexible time scale than previously possible.

20

In a preferred embodiment of the invention the bacterial storage method includes providing a nutrient medium for the stored bacteria.

25

A first solution may be prepared according to the invention containing a matrix protein and a mono-or di-saccharide in 100ml of buffer. It is optional to add a small amount, in the range of 0.01-1g of peptone.

30

A second solution may be prepared acting as a nutrient medium for the bacteria. This nutrient medium will routinely include essential nutrients for growth/survival of the bacteria. In addition, it may optionally also include bacterial membrane stabilizing components. The bacteria are grown/cultured

- 13 -

and then pelleted and mixed with a small volume of nutrient medium. A small volume of (1) the nutrient medium containing the viable bacteria is mixed with (2) a larger volume of the storage solution and subjected to drying as before to give a residual solid with water content approximately 4-8 percent by weight.

To re-constitute the viable bacterial sample the solid is dissolved in water or buffer or nutrient solution.

In another embodiment of the invention, a preparation of the biological material to be stored (B) is mixed with a solution of the invention (S) in a ratio {of B/S} of between 1:5 and 1:10. Volumes of the mixed solution in an amount of between 10 and 50 μ l are dispensed onto a hydrophobic film, for example parafilm, or into microtitre strips. This results in small separated liquid volumes. At this stage the biological material is in a stabilizing solution in a droplet of given volume which contains a desired quantity of biological material. The separated volumes are then dried to give residual solid lenticules or pellets with a water content in the range 4-8 percent by weight, preferably around 6 percent by weight.

The process differs from freeze drying in that the drying temperature is not below 0°C nor the pressure significantly below atmospheric. The stabilizing solution typically contains an initial level of around 30 percent dissolved solids. As drying proceeds, the individual volumes becomes highly viscous and, when on the hydrophobic film, assume the shape of a plano-convex disk, i.e. lens like. As drying proceeds further, the discs become solid and glass-like. Although the size and weight of the solid pellets can vary over a wide range, the invention is particularly applicable to the production of these relatively small solid pellets.

Typical pellets produced according to the invention may weigh less than 1mg and their weights can be as 1-100mg or lower. It will be appreciated

- 14 -

that the final weight and size is determined by the volume and concentration of the solution before drying commences and the water content of the solid. Thus, for example, when the volume of the solution being dried is in the range 1-100 μ l, preferably 10-50 μ l and the solid content is around 33 wt%,
5 the final dried weight will be around 0.33-33mg, preferably 3.3-16mg. The final dried solid discs are typically between 1-5mm in diameter. They are suitable thereafter for storage at 4°C or less, and preferable under desiccation, and will not deteriorate significantly at ambient temperature, e.g. if in transit. They can be stored at reduced temperature, down to -
10 20°C or lower, in the presence of a dehydrating substance, e.g. silica gel.

The precise composition of the stabilizing solution will vary according to the materials being preserved. For example, many buffers may be appropriate, though it is essential that the components of the buffer do not selectively
15 salt out as the concentration of the buffer increases as drying proceeds.

It will be appreciated that there is a degree of empiricism with the selection of the substances used in the stabilizing solution. The basic ingredients are designed to ensure that the solid material dries out into a glass like solid
20 which is firm and free of crystal formations. Other additional components may optionally be added such as glycerol (membrane stabilizing), ascorbic acid (reducing agent), peptone, amino acids, calcium, magnesium and phosphate ions, charcoal and soluble starch. These additional substances are typically present in amounts between 0.01 and 1 percent weight by
25 volume. The additional components are added to act as plasticizers, reducing agents, nutrients, membrane protectors and anti-oxidants.

Preferably the composition contains water in an amount of between 4-8% by weight of the total composition.

30

A marker dye is optional, functioning only for convenience in identifying the stored material. The same solution and method can be used for the storage

- 15 -

of conjugated antibody.

There is sometimes a marked reduction in the viable counts of some organisms, such as *Aeromonas*, during drying. Allowance must be made for this, but once dehydrated, no further increased loss of viability occurs.

Example 1

Storage Solution Formula

10 A solution is prepared having the following composition:-

	Trehalose	240 g
	Bovine serum albumin (filtered)	80 g
	Glucose	10 g
15	CMC (BDH, low viscosity)	20 g
	Pages saline (Oxoid)	1 litre

20 The BSA is analyzed and contains only 5 milli-equivalents of sodium. Pages saline is used because it stabilises biological entities. It is a dilute saline containing low concentrations of sodium, magnesium, potassium and phosphorus. Other buffers may also be used. EC-approved food colourings are added on occasion. All have been tested at high concentrations against various bacteria and had no deleterious effect on viability.

25 Once it has been made up, the solution is autoclaved prior to use. Note that the concentrations of the ingredients will increase during dehydration. If a 25 μ l drop dehydrates to c. 7mg i.e. c. 7 μ l, everything is concentrated by a factor of 3.

30 Example 2

Dehydration of the Storage Solution

- 16 -

A storage solution from Example 1 is subjected to forced drying under a draught of filtered air in a drying cabinet containing silica gel for a few hours (3-4 hours for individual lenticules on Parafilm strips; overnight when dispensed into the wells of plastic strips). Thereafter, they are transferred to sealed plastic boxes containing silica gel and left in the fridge at 4°C to complete the dehydration process, which may take 7 days. When they have become "hard", which seems to be judged by eye, they are transferred to screw-capped plastic jars containing silica gel and stored at -20°C. Samples are removed for viable count testing after 7 days and at 3-6 monthly intervals thereafter.

Drying the lenticules under reduced pressure is an option. The silica gel, in the base of the cabinet, is regenerated by heating it in a hot air oven until it is bright blue. Other desiccants may also be used.

Example 3

Preparation of bacteria for Solution.

Typically, the bacterial strain to be preserved is subcultured onto solid media to obtain heavy growth i.e. $c. 10^{11}$ colony forming units (cfu). After appropriate incubation (usually overnight at 37° C, such that the bacteria should be in the early lag phase of their growth cycle) the colonial growth is collected in a sterile loop, which holds $c. 100$ mg of material. This collected material is suspended in $c. 0.5$ ml Pages saline, which is then added to 2.5 ml of lenticulating solution and mixed very thoroughly to avoid clumping. Satisfactory mixing can be achieved by sucking a small volume up and down in a fine-tipped pipette.

Once an even suspension has been achieved, the inoculated fluid is dispensed in drops weighing $c. 1$ mg onto a hydrophobic surface such as Parafilm, stretched taut over a flat sheet of material such as Perspex. There should be sufficient for 100 such spots, each containing $c. 10^8$ cfu.

- 17 -

In order to make defined-count lenticules the inoculum can be factored down from these high-count "stock" lenticules. A Miles and Misra viable count is performed, and a lenticule is rehydrated in maximum recovery diluent (MRD), diluted appropriately in MRD and then added to lenticulating solution at the required concentration i.e. the low-count lenticules are prepared from the stock lenticules without a culture step.

Example 4

Preparation of cells from urine for preservation by lenticulation

White blood cells and epithelial cells from human urine are stored to be used in making simulated clinical samples for QA purposes.

1 litre of urine is pooled from clinical samples known to have high cell counts. The red blood cells are removed by adding 20ml glacial acetic acid dropwise, with stirring. This also dissolves the phosphates. The urine is allowed to stand so that the remaining cells will settle out slowly. It can not be centrifuged at this stage because that would cause the cells to stick together.

After a few hours, most of the supernatant is decanted off and approximately 100ml of 0.1M disodium, dihydrogen phosphate buffer at neutral pH is added to neutralise the acetic acid. The suspension is allowed to stand again and most of the supernatant is decanted. Phosphate buffered saline (PBS) is added to restore the volume to c. 100ml. This is now a suspension of white blood cells, epithelial cells and a few bacteria. One part in 800 of glutaraldehyde is added to fix the cells, preserving their morphology. The cells are pelleted by centrifuging at a slow speed such that the bacteria remain in the supernatant. The cells are rinsed once in PBS and can then be stored at -4°C or cryopreserved by the addition of 30% glycerol and storing at -20°C . They can be added to the storage solution of Example 1 at the desired concentration, with or without bacteria or other biological

- 18 -

material, and dehydrated in the usual manner.

Example 5

Preparation of red blood cells for lenticulation

5

Sheep red blood cells are prepared for storage by fixing them in glutaraldehyde as in Example 4 and sedimenting them.

- 19 -

Example 6**Preparation of simulated faeces**

5 Biodegradable plant material is dried, crushed and heat-treated with enteric pathogens to simulate faecal material for QA tests and stored using the solution of Example 1.

Example 7**Preparation of background flora for simulated throat swabs**

10

Blood agar plate cultures of throat swabs are selected containing no pathogenic bacteria, but a wide variety of typical, non-pathogenic, mouth flora. The biomass is pooled from several plates and stored as in Examples 1-3. Thereafter, these could be rehydrated and added to fresh lenticulating
15 solution at appropriate dilution to provide high, medium or low background counts. Suspensions of the target pathogen can be added, again at known concentrations, and the complex suspensions dispensed and dried as before. These can be used in National External Quality Assessment Schemes such as UKNEQAS.

20

Alternatively, the storage solution containing the background flora and pathogens is distributed and dehydrated in plastic cupules. The product is rehydrated with a defined volume of MRD. Standard cotton swabs are dipped into the suspension, as each will take up a standard volume, several
25 swabs being tested in each laboratory receiving the QC sample, according to their standard operating procedure (SOP) for culturing throat swabs.

Example 8**Other microorganisms preserved by lenticulation.**

30

Using the materials and methods of Examples 1-3, *Cryptosporidium* oocysts, certain fungi such as *Candida*, and *Mycoplasma* are stored. *Mycoplasma* are

- 20 -

5 cultured in broth for several days prior to storage. The cells are then spun out in a microfuge and resuspended in half the original volume in storage solution. The stored material is rehydrated on a solid medium and carefully spread over a circular area of *c.* 1cm radius. After several days' incubation, the surface of the plate is examined under a low-power microscope to view the colonies of Mycoplasma.

10 Viruses have been successfully stored, preserving their morphology for electron microscopy QA samples, and preserving viability in Influenza A and Adenoviruses for over a year.

Example 9

Rehydration of lenticules

15 Viable microorganisms are retrieved from the stored sample by rehydrating them. Typically, a stored sample can be placed on the surface of a suitably supportive solid medium such as blood agar, and allowed to rehydrate for 10 minutes. Thereafter, it can be spread with a sterile plastic loop over the surface of the plate in the usual way.

20 Alternatively, a stored sample can be added to a volume of a liquid, typically maximum recovery diluent (MRD) and allowed to dissolve completely. The liquid is then swirled to ensure even mixing and sampled as desired.

Example 10

Use of Preparation of the Invention in "spiking" dried foods for Food EQA Schemes.

30 Food EQA Schemes typical want to assess the ability to detect the presence or absence of very low counts (10 cfu in 25g dried food) of specific pathogens. Low-count preparations are particularly suited to this. Duplicate preparations each containing 10 cfu of the target organism (or not) are

- 21 -

supplied. One preparation is rehydrated directly onto solid media and a colony count performed. The other is added to 25g of dried food, which is then subjected to the laboratory process being controlled. One hundred per cent recovery is not expected, because of the presence of free radicals, toxins or competitor organisms in the food. A failure-to-detect rate of 5% is acceptable to the food industry, but ideally the reference material should be supplied close to the limit of detection to provide a sufficiently stringent test.

Thus, if more than 5% of the results from processed foods fail to correspond with those from the direct plating of the paired lenticules, further investigation of the processing is warranted. *Salmonella goldcoast* has been used in this work to date because it is a durable *Salmonella*, is monophasic and relatively uncommon.

To introduce such presence/absence lenticules into a Food EQA Scheme would be straightforward. The lenticule content could be dictated by the specific process to be controlled. The ability to produce up to 10,000 identical preparations at a time has the great advantage that replicate samples are available for any test laboratory experiencing difficulty with their food processes.

Example 11

Storage of simulated urine

Materials and Methods

STRAINS

Routine isolates from urinary tract infections were collected over a period of one month. These included *E coli*, "coliforms," *Klebsiella sp.*, *Pseudomonas* and *Str. faecalis*. In addition we selected NCTC strains of *Acinetobacter*, *Ps. fluorescens* MRSA and *C. albicans* to extend the range of organisms for inclusion in the panel. Strains were chosen for their typical colonial appearances, plated onto a supportive medium, usually blood agar, and

- 22 -

incubated overnight or longer for maximal yield. These cultures were preserved by the method of Example 1 and stored at -20°C pending further tests. A proportion of the lenticules were held at room temperature, 30°C and 37°C for 7 days reconstituted and cultured. Strains showing a substantial fall in count at the higher temperatures were rejected on the premise that an accelerated degeneration test would predict their probable long term storage. Pus and epithelial cells from the urinary tract were collected by pooling a substantial number of fresh urine samples submitted for routine examination. To one litre of this pool 20ml of glacial acetic acid was added and quickly mixed. After standing at room temperature for 4 hours most of the cellular content had settled into the bottom 20% volume. The supernatant was decanted and the remaining 200ml centrifuged very lightly at 1,000 rpm, to deposit the cells. These were washed twice in PBS and cryo-preserved at -20°C as a 10% suspension until required. Group O positive red cells were also cryo-preserved as a 10% suspension at -20°C.

Urine specimens were made from the stored bacteria and the cryo-preserved suspensions of cells by reconstitution in storage solution at a predetermined level. These levels were set to resemble those of fresh urine samples and included counts above and below 10^5 CFU's either of single organisms or mixtures. In addition some samples contained pus cells or red cells or both at an easily observable concentration. The mixtures were dispensed into 8 well flat bottomed microtitre strips each position being occupied by a different sample. Four batches were made giving a total of 32 samples. However one sample was replicated in batches 2, 3 and 4. The set also included some completely negative samples. The batches of strips were assembled into plates, labelled and dried by forced ventilation in a desiccating cabinet at 20°C followed by standing at 4°C for 72 hours over silica gel to complete the process. The plates were stored at -20°C pending use.

MEDIA

- 23 -

All routine culture media was supplied by Oxoid in powder form which was prepared on site in accordance with the manufacturer's instructions. Columbia Agar Base CM331 with 5% horse blood from TCS for Blood Agar plates, CLED CM. Solutions were prepared as needed from stock reagents.

5

PROCEDURE FOR TESTING

Prior to use the strips were re-hydrated by the addition of 100 μ m of MRD to each well, left for 10 minutes and shaken to disperse the bacterial and cellular suspensions. These specimens were examined by the laboratory's standard operating procedure. Cells were observed with an inverted microscope with the specimens in situ. Care was needed to ensure that the strips were correctly orientated as the identification of each sample depended upon its position, 1-8, in the strip. Each specimen was spread using a standard 1 μ l loop onto half of a standard 90mm CLED plate and incubated overnight aerobically at 37°C. The plates were read, scored and recorded by the same individual that processed the specimen the previous day. Sensitivity tests and identifications were carried out on a some of the isolates.

10

15

20

All specimens in the four batches were tested independently at various times for over a year both by microscopy and culture to ascertain their keeping properties. To improve the accuracy of these tests the counts were done by Miles and Misra (1938, Journal of Hygiene, 38, pp 732-749) as the volumes picked up by the standard loop method vary considerably.

25

RESULTS

The results are shown in Table A.

- 24 -

TABLE A

Survival of Organisms in Simulated Urine, CFU's per ml

5

Sample	Organism	90 Days	180 Days	360 Days	35 Months
A	E Coli	2.5×10^4	6.5×10^4	3.6×10^4	7.2×10^4
B	E Coli	1.7×10^6	1.6×10^6	2.6×10^6	1.8×10^6
C	Str faecalis	4.9×10^5	8.5×10^5	8.5×10^5	8.0×10^5
D	Klebsiella	6.7×10^5	8.8×10^5	1.0×10^6	<u>1.0×10^4</u>
E	Pseudomonas	1.9×10^5	4.0×10^5	2.7×10^5	2.0×10^5
F	E Coli	6.5×10^4	8.7×10^4	1.0×10^5	5.3×10^4
G	Str faecalis	1.2×10^5	3.5×10^5	2.3×10^5	3.5×10^5

10

15

20

The results show no evidence of falling counts on preserved organisms over a period of one year or, with the single exception of the Klebsiella sample, 35 months. In addition the morphology of the cellular components of the samples remained unaltered.

25

- 25 -

Example 12**Storage of *E Coli***

5 Lenticules containing *E Coli* were prepared according to Example 3 and viable counts on blood agar or on storage solution taken at day 1, 90 and 220. The results are shown in table B.

10 Thus, the invention provides an efficient method of storing biological materials in solid form. The materials are acceptably stable in solid form and are easily reconstituted into working solution. Many practical applications of the invention are evident, such as storage of bacterial samples for transit.

TABLE B

E coli NCTC 12950 batch 980521 Counts on groups of 30 lenticules.

		60	79	81	82	87	87	
5	On Blood Agar (BA) Day 1	60	79	81	82	87	87	
		89	90	90	90	92	92	
		93	94	94	95	96	96	
10		97	97	100	100	101	101	
		102	103	104	105	105	109	mean 94
	On Example 1 Solution (ES) Day 1	48	50	53	53	54	54	
15		55	55	56	56	56	57	
		57	57	58	58	60	61	
		61	61	64	64	66	66	
		66	66	66	68	70	70	mean 59
20	On ES Day 90	57	66	61	54	69	75	
		47	44	54	55	62	55	
		59	56	56	60	69	56	
		51	67	57	65	51	65	
		63	58	69	67	54	57	mean 59
25	On ES Day 220	40	46	50	51	51	54	
		54	55	55	56	56	56	
		56	56	57	57	58	58	
		58	60	61	61	61	63	
30		65	66	67	69	69	69	mean 58
	On BA Day 220	74	74	74	78	80	80	
		80	82	82	83	83	83	
		84	84	84	84	85	86	
35		86	89	89	90	90	93	
		94	98	100	102	102	void	mean 86

- 27 -

CLAIMS

1. A composition for preserving viable microorganisms, cells or tissue, the composition comprising:

5

- (a) a preservative combination of (i) a non-reducing disaccharide and (ii) a bulking agent; and
- (b) a buffer.

10

2. A composition according to Claim 1 wherein the weight ratio of the non-reducing disaccharide : bulking agent is 5:1 to 0.5:1.

3. A composition according to Claims 1 or 2 wherein the weight ratio of the non-reducing disaccharide : bulking agent is 3.5:1 to 1.5:1.

15

4. A composition according to any preceding claim wherein the non-reducing disaccharide is selected from the group consisting of trehalose, sucrose, maltose, lactose, cellobiose, isomers thereof and mixtures thereof.

20

5. A composition according to Claim 4 wherein the disaccharide comprises trehalose.

6. A composition according to any preceding claim wherein the bulking agent is, or comprises, a high molecular weight protein.

25

7. A composition according to Claim 6 wherein the bulking agent is an albumin.

8. A composition according to any preceding claim, comprising:

30

- (i) 5 to 30 wt% non-reducing disaccharide;
- (ii) 1 to 10 wt% bulking agent; and

- 28 -

(iii) 60 to 94 wt% aqueous buffer.

9. A composition according to any preceding claim, further comprising a monosaccharide.

5

10. A composition according to Claim 9 wherein the monosaccharide is a reducing sugar.

10

11. A composition according to Claim 10 wherein the reducing sugar is glucose.

12. A composition according to any of Claims 9-11 comprising 0.1 to 3 wt% monosaccharide.

15

13. A composition according to any preceding claim, further comprising a structural additive.

14. A composition according to Claim 13 wherein the structural additive is, or comprises, a water-soluble polymeric carbohydrate.

20

15. A composition according to any of Claims 13 or 14 wherein the structural additive is carboxymethylcellulose or hydroxyalkylcellulose.

25

16. A composition according to any preceding claim further comprising a colouring agent.

17. A composition according to any preceding claim wherein the microorganisms are selected from the group consisting of bacteria, viruses, protozoa and fungi.

30

18. A composition according to any preceding claim wherein the solids content is in the range of from 10-50%.

- 29 -

19. A process for preserving viable microorganisms, cells or tissue, comprising the steps of:

- 5 (a) combining the microorganisms, cells or tissue with the composition of any of Claims 1 to 18 to form a preserving preparation,;
- (b) drying the preserving preparation at above the triple point of water; and
- (d) storing the dried preparation obtained.

10

20. A process according to Claim 19 wherein step (b) is carried out at atmospheric pressure.

15

21. A process according to Claim 19 or Claim 20 wherein step (b) is carried out by passing a draught of air, inert gas or a mixture thereof over the preserving preparation in the presence of a drying agent.

22. A process according to Claim 21 wherein step (b) comprises:

20

- (i) partially drying the preserving preparation by passing a draught of air, inert gas or a mixture thereof over the preserving preparation in the presence of a drying agent; and

25

- (ii) subjecting the partially dried preserving preparation to further drying at reduced temperature.

23. A process according to any of Claims 21-22 wherein the drying agent is silica gel.

30

24. A process according to any of Claims 19-23 comprising drying the preserving preparation at reduced pressure.

- 30 -

25. A process according to any of Claims 19-24 comprising depositing the preserving preparation onto a hydrophobic surface prior to drying.

5

26. A process according to Claim 25 wherein the volume of preserving preparation deposited onto the hydrophobic surface is in the range of from 5-100 μ l.

10

27. A process according to any of Claims 19-26 wherein one or more of the steps (a) to (c) are carried out in a substantially oxygen-free environment.

15

28. A dried composition according to any of Claims 1-16 further comprising a viable microorganism and having a solids content of at least 80%.

29. A dried composition according to Claim 28 wherein the viable microorganisms are bacteria, or a mixture of bacteria of different strains, or a combination of bacteria and mammalian cells.

20

30. A dried composition according to any of Claims 28-29 having a defined microorganism count wherein said microorganism count remains substantially stable in storage at reduced temperature.

25

31. A dried composition according to any of Claims 28-30 wherein the composition is fully dispersible when reconstituted with water or aqueous buffer solution.

30

32. A method of preserving viable microorganisms, cells or tissue, comprising:-

- a combining viable microorganisms, cells or tissue with a preserving solution comprising a non-reducing disaccharide;

- 31 -

b drying the combination of (a) to form a dried preparation having a solids content of at least 80% by weight; and

5 (c) counting the viable microorganisms, cells or tissue in the dried preparation;

whereby the dried preparation can be combined with aqueous buffer to yield an aqueous preparation comprising a predetermined count of viable microorganisms, cells or tissue.

10

33. A method of preserving viable microorganisms, comprising drying an aqueous preparation of viable microorganisms in the presence of non-reducing disaccharide to form a dried preparation, counting the viable microorganisms in the dried preparation to obtain a counted dried preparation, and storing the counted dried preparation, wherein the counted dried preparation when reconstituted with water or aqueous medium forms an aqueous preparation containing a predetermined number of viable microorganisms.

15

20 34. A method according to Claim 32 or 33 wherein the method comprises forming at least first and second dried preparations, counting the viable microorganisms, cells or tissue in the first dried preparation and thereby estimating the number of viable microorganisms, cells or tissue in the second dried preparation.

25

35. A method according to Claim 34 comprising forming a plurality of dried preparations, and counting a selected sample of those dried preparations so as to estimate the count of viable microorganisms, cells or tissue in the remaining dried preparations.

30

36. A compositions for preserving viable microorganisms, cells or tissue substantially as hereinbefore described with reference to the examples.

- 32 -

37. A process for preserving viable microorganisms, cells or tissues substantially as hereinbefore described with reference to the examples.

5 38. A dried composition comprising viable microorganisms, cells or tissues substantially as hereinbefore described with reference to the examples.